Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license
To report a serious adverse event or obtain product information, contact 1-866-280-2852.
While tirzepatide has substantial evidence supporting its approval for obesity treatment, Lilly has shown it to deliver better results than semaglutide in the SURMOUNT-5 trial
Add to that years of habitual sugar consumption, and you have a recipe for cravings that medications alone cant fully suppress
In the most recent study, researchers said the vast majority of websites did not ask for quantitative patient data prior to prescribing